PRKAA1 and neoplasm: Indeed, when analyzing tumor tissue samples, we found that NPC-26 administration (12 hours after initial administration) induced significant AMPK activation, or p-AMPK/p-ACC, in control tumors (Figure 5B, left panel), which was absent in tumors expressing AMPKα1 shRNA (Figure 5B, left panel).